Source: Annual Congress 2001 - Early lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. M. Lang, D. F. Stratakis, J. Benedikter, S. Gallenberger, M. Maehle, R. M. Huber (Munich, Germany). Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC). Eur Respir J 2001; 16: Suppl. 31, 244

Member's Comments

No comment yet.

Related content which might interest you: Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Liquid biopsy for EGFR mutations in non-small cell lung cancer cases by RT-PCR Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Frequency of T790M substitution in exon 20 of EGFR gene in brain metastases in chemotherapy-naive non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Comparing exhaled molecular profiles of patients with non-small cell lung cancer (NSCLC) with those of patients with non-pulmonary malignancy Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease Year: 2010 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012